Omniome, Inc., US based developer of an innovative new DNA sequencing platform, has raised an additional $60 million with the completion of its Series B financing.  The funding round was led by Decheng Capital (Shanghai) and Hillhouse Capital Group (Beijing), joined by Lam Research Capital (US) and Nan Fung Life Sciences (Hong Kong) as well as current investors ARCH Venture Partners, Domain Associates, Biomatics Capital Partners and Altitude Life Science Ventures.

A portion of the proceeds from the financing will be used to expand the company's capabilities by hiring new team members across multiple disciplines, particularly in engineering, and building out additional research and production capacity. The company will continue to optimize the novel Sequencing By Binding (SBB) technology while accelerating prototype development of commercially-impactful sequencing platforms.